RU2014119879A - Способ снижения прилива крови к лицу при систематическом использовании ингибиторов фосфодиэстеразы типа 5 - Google Patents
Способ снижения прилива крови к лицу при систематическом использовании ингибиторов фосфодиэстеразы типа 5 Download PDFInfo
- Publication number
- RU2014119879A RU2014119879A RU2014119879/15A RU2014119879A RU2014119879A RU 2014119879 A RU2014119879 A RU 2014119879A RU 2014119879/15 A RU2014119879/15 A RU 2014119879/15A RU 2014119879 A RU2014119879 A RU 2014119879A RU 2014119879 A RU2014119879 A RU 2014119879A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- receptor agonist
- adrenergic receptor
- skin
- acceptable salt
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 19
- 239000008280 blood Substances 0.000 title claims abstract 7
- 210000004369 blood Anatomy 0.000 title claims abstract 7
- 230000009897 systematic effect Effects 0.000 title claims abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 20
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims abstract 19
- -1 nefazolin Chemical compound 0.000 claims abstract 11
- 229960001528 oxymetazoline Drugs 0.000 claims abstract 10
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims abstract 9
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims abstract 8
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims abstract 8
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 claims abstract 8
- 229960003679 brimonidine Drugs 0.000 claims abstract 7
- 239000000203 mixture Substances 0.000 claims abstract 7
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- 238000011010 flushing procedure Methods 0.000 claims abstract 5
- WXFIGDLSSYIKKV-RCOVLWMOSA-N L-Metaraminol Chemical compound C[C@H](N)[C@H](O)C1=CC=CC(O)=C1 WXFIGDLSSYIKKV-RCOVLWMOSA-N 0.000 claims abstract 4
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 claims abstract 4
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims abstract 4
- RXQCGGRTAILOIN-UHFFFAOYSA-N mephentermine Chemical compound CNC(C)(C)CC1=CC=CC=C1 RXQCGGRTAILOIN-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960003663 metaraminol Drugs 0.000 claims abstract 4
- 229960005192 methoxamine Drugs 0.000 claims abstract 4
- 229960000337 tetryzoline Drugs 0.000 claims abstract 4
- 229960000833 xylometazoline Drugs 0.000 claims abstract 4
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims abstract 3
- 229960001094 midodrine Drugs 0.000 claims abstract 3
- PTKSEFOSCHHMPD-UHFFFAOYSA-N midodrine Chemical compound COC1=CC=C(OC)C(C(O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims abstract 3
- 239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 claims abstract 2
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims abstract 2
- 230000000699 topical effect Effects 0.000 claims abstract 2
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical group O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims 1
- 229960001724 brimonidine tartrate Drugs 0.000 claims 1
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 claims 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical group Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548844P | 2011-10-19 | 2011-10-19 | |
| US61/548,844 | 2011-10-19 | ||
| PCT/IB2012/002500 WO2013057579A2 (en) | 2011-10-19 | 2012-10-12 | Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014119879A true RU2014119879A (ru) | 2015-11-27 |
Family
ID=47631462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014119879/15A RU2014119879A (ru) | 2011-10-19 | 2012-10-12 | Способ снижения прилива крови к лицу при систематическом использовании ингибиторов фосфодиэстеразы типа 5 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9744168B2 (enExample) |
| EP (1) | EP2768502A2 (enExample) |
| JP (1) | JP2014530846A (enExample) |
| KR (1) | KR20140091543A (enExample) |
| CN (1) | CN103889417A (enExample) |
| AU (1) | AU2012324543B2 (enExample) |
| BR (1) | BR112014009210A2 (enExample) |
| CA (1) | CA2850273A1 (enExample) |
| IL (1) | IL231820A0 (enExample) |
| MX (1) | MX2014004383A (enExample) |
| PH (1) | PH12014500783A1 (enExample) |
| RU (1) | RU2014119879A (enExample) |
| WO (1) | WO2013057579A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120076738A1 (en) * | 2010-09-28 | 2012-03-29 | Michael Graeber | Combination treatment for dermatological conditions |
| WO2015191917A1 (en) * | 2014-06-11 | 2015-12-17 | Allergan, Inc. | Stabilized oxymetazoline formulations and their uses |
| WO2018065546A1 (en) * | 2016-10-07 | 2018-04-12 | Micreos Human Health B.V. | Vasoconstricitve and antibacterial combination treatment for rosacea |
| KR102122980B1 (ko) * | 2018-12-28 | 2020-06-18 | 한국프라임제약주식회사 | 들깨 잎 추출물을 유효성분으로 함유하는 갱년기 관련 안면홍조 완화용 조성물 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3278447A (en) | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
| DE2436882A1 (de) | 1974-07-29 | 1976-02-19 | Schering Ag | Neue oxyphenylbutazon-derivate und ihre herstellung |
| DE2436883C2 (de) | 1974-07-29 | 1985-08-22 | Schering AG, 1000 Berlin und 4709 Bergkamen | Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| DE2632678C2 (de) | 1976-07-16 | 1986-02-27 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6α-Fluor-12α-Halogen-Kortikoide und Verfahren zu ihrer Herstellung |
| NZ185295A (en) | 1976-10-04 | 1980-04-28 | Schering Ag | 9-chloroprednisolone derivatives and pharmaceutical compositions |
| US4285967A (en) | 1978-06-30 | 1981-08-25 | Estee Lauder Inc. | Cosmetic preparation for reducing redness of blemishes |
| US4908387A (en) | 1988-06-06 | 1990-03-13 | The Regents Of The University Of California | Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis |
| CA2003198C (en) | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
| US5736165A (en) | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
| ES2187533T3 (es) | 1993-10-13 | 2003-06-16 | Allergan Inc | Usdo de derivados de (2-imidazolin-2-ilamino)quinoxalina. |
| US6117871A (en) | 1993-12-17 | 2000-09-12 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists |
| WO2000023066A2 (en) | 1998-10-20 | 2000-04-27 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| CA2154979A1 (en) | 1995-07-28 | 1997-01-29 | Kenneth T. Armstrong | Topical phenylephrine preparation |
| US5910312A (en) | 1996-10-09 | 1999-06-08 | Ideal Ideas, Inc. | Acne treatment composition with vasoconstrictor |
| SE9901295D0 (sv) | 1999-04-13 | 1999-04-13 | Jan Hedner | Sätt och medel för att förebygga, behandla och diagnostisera kardiovaskulära komplikationer hos patienter med obstruktiv sömnapné |
| ES2199094T1 (es) | 1999-08-19 | 2004-02-16 | Lavipharm Sa | Polimeros formadores de pelicula, procedimientos de uso y aplicaciones de los mismos. |
| US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| CA2402405C (en) | 2000-07-14 | 2008-02-12 | Allergan Sales, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| US6680062B2 (en) | 2001-10-05 | 2004-01-20 | Color Access, Inc. | Anti-irritating rosacea treatment |
| US7345065B2 (en) | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
| US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| US7812049B2 (en) * | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| CA2567401C (en) * | 2004-05-25 | 2013-11-12 | Sansrosa Pharmaceutical Development, Inc. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
| US20090061020A1 (en) | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
| EP2230910A4 (en) | 2007-12-21 | 2011-04-13 | Galderma Lab Inc | PRE-SURGICAL TREATMENT |
| KR20110017365A (ko) | 2008-05-30 | 2011-02-21 | 페어필드 클리니컬 트라이얼즈 엘엘씨 | 피부 염증 및 변색을 위한 방법 및 조성물 |
| WO2009152344A2 (en) * | 2008-06-11 | 2009-12-17 | Comgenrx, Inc. | Combination therapy using phosphodiesterase inhibitors |
| EP2493475A4 (en) | 2009-10-30 | 2014-10-29 | Intratus Inc | COSMETIC METHODS AND PREPARATIONS FOR THE PROLONGED RELEASE OF THERAPEUTIC AGENTS IN THE EYE |
| MX2012010824A (es) | 2010-03-26 | 2012-10-10 | Galderma Res & Dev | Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema. |
-
2012
- 2012-10-12 BR BR112014009210A patent/BR112014009210A2/pt not_active IP Right Cessation
- 2012-10-12 CA CA2850273A patent/CA2850273A1/en not_active Abandoned
- 2012-10-12 WO PCT/IB2012/002500 patent/WO2013057579A2/en not_active Ceased
- 2012-10-12 PH PH1/2014/500783A patent/PH12014500783A1/en unknown
- 2012-10-12 CN CN201280051534.6A patent/CN103889417A/zh active Pending
- 2012-10-12 KR KR1020147011912A patent/KR20140091543A/ko not_active Withdrawn
- 2012-10-12 AU AU2012324543A patent/AU2012324543B2/en not_active Expired - Fee Related
- 2012-10-12 JP JP2014536349A patent/JP2014530846A/ja active Pending
- 2012-10-12 US US14/344,099 patent/US9744168B2/en not_active Expired - Fee Related
- 2012-10-12 EP EP12821025.9A patent/EP2768502A2/en not_active Withdrawn
- 2012-10-12 MX MX2014004383A patent/MX2014004383A/es unknown
- 2012-10-12 RU RU2014119879/15A patent/RU2014119879A/ru not_active Application Discontinuation
-
2014
- 2014-03-31 IL IL231820A patent/IL231820A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140343067A1 (en) | 2014-11-20 |
| AU2012324543B2 (en) | 2017-08-10 |
| WO2013057579A2 (en) | 2013-04-25 |
| IL231820A0 (en) | 2014-05-28 |
| AU2012324543A1 (en) | 2014-05-01 |
| EP2768502A2 (en) | 2014-08-27 |
| PH12014500783A1 (en) | 2014-05-12 |
| WO2013057579A3 (en) | 2013-07-04 |
| JP2014530846A (ja) | 2014-11-20 |
| KR20140091543A (ko) | 2014-07-21 |
| MX2014004383A (es) | 2014-11-12 |
| CN103889417A (zh) | 2014-06-25 |
| CA2850273A1 (en) | 2013-04-25 |
| US9744168B2 (en) | 2017-08-29 |
| BR112014009210A2 (pt) | 2017-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| MX345032B (es) | Antagonistas del receptor ep4 para el tratamiento de cáncer. | |
| PH12014501277A1 (en) | Kinase inhibitors | |
| PE20081635A1 (es) | Agentes para suprimir la reaccion de rechazo cronica | |
| EA200970935A1 (ru) | Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа | |
| EA201170676A1 (ru) | Агонисты рецептора меланокортина | |
| EA201500484A1 (ru) | Лечение или профилактика сердечно-сосудистых явлений с использованием производного колхицина | |
| RU2013113184A (ru) | Комбинированное лечение розацеа | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| EA201071038A1 (ru) | Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| RU2014119879A (ru) | Способ снижения прилива крови к лицу при систематическом использовании ингибиторов фосфодиэстеразы типа 5 | |
| JOP20220329A1 (ar) | مضاد مستقبل crf1 لعلاج فرط تنسج الكظر الخلقي | |
| EA201100409A1 (ru) | Замещенные производные триазолопиридазина | |
| CY1114163T1 (el) | Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση | |
| CY1109763T1 (el) | Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης | |
| RU2013110003A (ru) | Комбинация соединений для лечения или предотвращения кожных заболеваний | |
| EA201071229A1 (ru) | Производные иминопиридина и их применение | |
| MX2014006629A (es) | Inhibidores de cinasa. | |
| MX2012001160A (es) | Agonistas del receptor de esfingosina-1-fosfato. | |
| EA201071395A1 (ru) | Ингибитор толерантности к анальгетику | |
| EA200970764A1 (ru) | Способ лечения расстройств, вызванных пролиферацией клеток, с применением стимуляторов секреции гормона роста | |
| RU2013123043A (ru) | Гелевая композиция для местного применения | |
| TN2014000060A1 (en) | Benzothiazolone compound | |
| MX2007006081A (es) | Tetrahidroisoquinolinas 4-fenil-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170911 |